Sientra to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN) announced it will release its financial results for Q4 and the full year of 2020 on March 11, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company specializes in medical aesthetics, particularly focused on plastic surgeons, and offers a range of FDA-approved products, including advanced breast implants and the miraDry system for sweat and hair reduction. Investors can access the webcast on Sientra’s website, where relevant updates are also posted.

SANTA BARBARA, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Thursday, March 11, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 3371629.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Contact
Investor Relations
805-679-8885

FAQ

When will Sientra announce its Q4 2020 financial results?

Sientra will announce its Q4 2020 financial results on March 11, 2021, after market close.

What time is the Sientra conference call for Q4 2020 results?

The conference call to discuss Sientra's Q4 2020 results will take place at 4:30 p.m. ET on March 11, 2021.

How can I access Sientra's financial results webcast?

You can access the live webcast of Sientra's financial results on their Investor Relations section of the website.

What products does Sientra offer?

Sientra offers a range of products, including FDA-approved breast implants and the miraDry system for permanent hair and sweat reduction.